This provides a rationale for also targeting the ErbB-ERK axis in the MK2206-treated PCa cells (Figure 5A, one should compare the lanes 3 and 4 vs. lanes 7 and 8 in DU145 cells, respectively; Figure 5B, one should compare the lanes 3 and 4 vs. lanes 7 and 8 in DU145/Doc cells, respectively). The gene discussed is EGFR; the disease is posterior cortical atrophy.